Introduction
The anticancer drug methotrexate kills cells via strong inhibition of the enzyme dihydrofolate reductase [E. C. 1.5.1.3], thus causing depletion of tetrahydrofolate and hence of thymidylate and other metabolites on which DNA synthesis vitally depends. In efforts to overcome the problems associated with its use, various latent forms (pro-drugs) of methotrexate, e. g. monoamides (1) have been evaluated. The 2,4-diaminopyrimidine moiety of methotrexate is essential for tight binding to dihydrofolate reductase while the a-and γ-carboxylate groups are important for folate-type transport into cells. The 2-and 4-(aaminoacyl) and 2,4-di-(a-aminoacyl) derivatives of methotrexate are thus potential pro-drugs of methotrexate.
The long-term aim of this work is to activate appropriate pro-drug derivatives of methotrexate by enzyme -antibody conjugates designed to localize around tumour cells (2) . The strategy requires that the pro-drug chosen should not be cleaved prematurely by endogenous enzymes. The appropriate aamino acid units attached to methotrexate are thus to be selected based on the known specificities of aminopeptidases from human liver, kidney (3) and serum. For cleavage of these N-(a-aminoacyl) derivatives to the active drug, the activating enzymes chosen will be aminopeptidases or related enzymes found in microorganisms, plants or animals.
Material and Methods
In an earlier project 2-leucyl-and 2-alanylmethotrexate were synthesized (4) for their potential to be selectively cleaved by endogenous aminopeptidases which have been reported to be elevated at some tumour sites. As in our earlier work, methotrexate was, prior to acylation, protected as its di-t-butyl ester. Acetylation of folic acid had been reported to lead to cyclization of the glutamate moiety. In the present work methotrexate (Lederle) (0.30 g) was stirred at room temperature and with protection from light in excess t-butyl acetate (50 ml) containing 70% aqueous perchloric acid (0.6 ml), with t-butanol (10 ml) added to increase solubility. After 4 days the solution, diluted with ethyl acetate, was added to excess aqueous sodium bicarbonate. The organic layer was washed with water until neutral, dried over anhydrous sodium sulphate, and evaporated to give methotrexate di-t-butyl ester. The yield after purification by "flash chromatography" over a short column of silica gel (with elution using 2 to 10% methanol in chloroform) was 30%. Methotrexate di-t-butyl ester was coupled with N-t-butyloxycarbonyl-(BOC) α-amino acids (2 equivalents) at 45 °C using as coupling reagents dicyclohexylcarbodiimide, dicyclohexylcarbodiimide with N-hydroxysuccinimide, or 1,1'-carbonyldiimidazole (2 equivalents) in ethyl acetate or dichloromethane. The method is similar to that described earlier for coupling with dicyclohexylcarbodiimide (4).
The resulting mixture was separated by chromatography into the 2-(N-BOC-oc-aminoacyl), the 4-(N-BOC-a-aminoacyl), and the 2,4-di(N-BOC-oc-aminoacyl) derivatives of methotrexate di-t-butyl ester (typical yields: 20%, 20%, 30% respectively). On brief treatment with trifluoroacetic acid at room temperature and evaporation under reduced pressure of this reagent, each 2-(N-BOC-a-aminoacyl) methotrexate di-t-butyl ester yielded the corresponding 2-a-aminoacylmethotrexate in quantitative yield.
Results and Discussion
Several series of 2-(N-BOC-a-aminoacyl), 4-(N-BOC-α-aminoacyl) and 2,4-di(N-BOC-a-aminoacyl) derivatives of methotrexate di-t-butyl ester incorporating the following α-amino acids have been synthesized: isoleucine, norleucine and leucine. As in our previous work (4), the fully protected mono-and disubstituted derivatives were recognized through their chemical ionization mass spectra (obtained using a desorption probe and ammonia as ionizing gas) and the amino acid signals in the "C-NMR spectra, while distinction between the 2-and 4-substituted compounds (as well as the 2,4-disubstituted ones) was by comparison of the ultraviolet absorption characteristics and the pteridine signals in the "C-NMR spectra. Only the 2-(N-BOC-a-aminoacyl) derivatives of methotrexate di-t-butyl ester were de-protected by trifluoroacetic acid in this work, since we found earlier that the 4-and 2,4-acylated products were unstable to the reagent (4).
As discussed in the introduction, the 2-oe-aminoacyl derivatives of methotrexate synthesized were chosen with consideration for resistance to hydrolytic cleavage by endogenous aminopeptidases. To check on this point, they were incubated for 45 min at 39 °C with human plasma and, for comparison, phosphate buffer at pH 7.3. It was found by HPLC analysis that in either medium conversion to methotrexate was minimal, but some less polar decomposition product was formed irrespective of whether or not L-or D-aminoacyl moieties were involved. The nature of the aaminoacyl group was found to influence the HPLC retention times of the decomposition products, suggesting that the decomposition products retain at least in part the original aminoacyl moiety.
The decreased stability of the 2,4-diaminopteridine ring upon N-acylation is obviously related to the decreased ring stabilization upon electron-withdrawal (5). To illustrate, Rosowsky et al. have reported on the instability of methotrexate and aminopterin analogues with the electron-donating 2-amino group replaced by hydrogen or methyl (6) . In the present case, the free amino group of the a-aminoacyl moiety appears to participate in the decomposition process, since the protected 2-(N-BOC-aminoacyl) derivatives of methotrexate di-t-butyl ester were stable in a mixture of neutral phosphate buffer and methanol. Work is in progress to design modified versions of 2-otaminoacylmethotrexate with increased stability.
